Headlands Researchhas announced the acquisition of Clinvest Research, an established site based in Springfield, Missouri. Founded in 1996, Clinvest Research has conducted over 600 trials for chronic diseases and conditions such as headache and migraine, arthritis and chronic pain, and diabetes, as well as weight loss.
By combining Clinvest Research’s expertise with the 11 other sites in the Headlands Research site network studying chronic conditions, Headlands Research is able to access a greater participant population for clinical trials conducted in the US and Canada.
Headlands Research also recently announced the launch of Headlands Research Detroit as well as the acquisition of Headlands Eastern Massachusetts and has plans to continue expanding its network throughout 2023.
Headlands Research Acquires Clinvest Research — the Clinical Research Site Network’s Third Addition of 2023. (2023, May 4). Business Wire.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.